This week on Contemporary OB/GYN: July 26 to July 30

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

September 29th 2023

FDA updates warning for liver injury due to fezolinetant

Listen

Kevin Kunzmann

The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

September 15th 2023

SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances

Listen

The Menopause Society reports low rates of hormone therapy usage

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

Safety and efficacy of fezolinetant proven in Hispanic women

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.

Related Content

Celeste Krewson, Assistant Editor;Joshua Fitch, Senior Editor

September 17th 2024

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

September 29th 2023

FDA updates warning for liver injury due to fezolinetant

Listen

Kevin Kunzmann

The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

September 15th 2023

SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances

Listen

The Menopause Society reports low rates of hormone therapy usage

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.